In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects

Journal of Clinical Pharmacology
Yan LiSimon Zhou

Abstract

Pomalidomide is an immunomodulatory drug, and the dosage of 4 mg per day taken orally on days 1-21 of repeated 28-day cycles has been approved in the European Union and the United States to treat patients with relapsed/refractory multiple myeloma. In vitro data showed that pomalidomide is a substrate of multiple cytochrome P450 (CYP) isozymes and that its oxidative metabolism is mediated primarily by CYP1A2 and CYP3A4, with minor contributions from CYP2C19 and CYP2D6. The effect of CYP1A2 inhibition by fluvoxamine (a strong CYP1A2 inhibitor) and CYP1A2 induction by smoking on pomalidomide pharmacokinetics in healthy subjects has been assessed in 2 separate phase 1 open-label, single-dose studies. Following administration of a single oral dose of 4 mg pomalidomide, the plasma exposure when coadministered with fluvoxamine was 225.1% and 123.7% of that when administered alone for the total plasma exposure (AUC0-inf ) and the plasma peak exposure (Cmax ), respectively. In smokers with elevated CYP1A2 activity demonstrated by high caffeine clearance (a marker of CYP1A2 induction), the AUC0-inf was 32.3% lower, whereas the Cmax was 14.4% higher than that in nonsmokers. In addition, pomalidomide was safe and well tolerated as a single...Continue Reading

References

Jun 1, 1994·American Journal of Public Health·J Schein
Nov 1, 1995·The Annals of Pharmacotherapy·J R Schein
Jul 31, 1999·Clinical Pharmacokinetics·S Zevin, N L Benowitz
Jan 11, 2005·British Journal of Haematology·Toshiaki HayashiKenneth C Anderson
Mar 21, 2006·Critical Care Nursing Clinics of North America·Lisa A Kroon
Sep 8, 2007·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Lisa A Kroon
Apr 2, 2009·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·Espen Molden, Olav Spigset
Apr 8, 2010·Swiss Medical Weekly·Raffaela BertoliE Bernasconi
Apr 5, 2011·Clinical Therapeutics·Frank G A JansmanUNKNOWN Dutch Society of Clinical Pharmacology and Biopharmacy (NVKF&B)
May 20, 2011·Clinical Pharmacology and Therapeutics·M DobrinasC B Eap
Dec 4, 2012·Cancer Chemotherapy and Pharmacology·Matthew HoffmannGondi Kumar
Aug 22, 2013·Expert Opinion on Drug Metabolism & Toxicology·Francesca GaySara Bringhen
May 17, 2014·The Journal of Pharmacology and Experimental Therapeutics·Yan LiMaria Palmisano
Mar 26, 2016·Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society·Ghulam MurtazaTahir M Khan
Oct 21, 2016·Clinical Pharmacokinetics·Gail D Anderson, Lingtak-Neander Chan
Sep 2, 2016·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Kaoru TorigoeHiroyuki Achiwa
Nov 18, 2016·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Makiko ShimizuHiroshi Yamazaki
Jan 9, 2017·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Kim DaoSébastien Kissling

❮ Previous
Next ❯

Methods Mentioned

BETA
blood draw

Software Mentioned

POMALYST
SAS
PhoenixWinNonlin Professional

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.